A 75-year-old woman, who underwent bilateral cataract surgery 2 years ago, presented with a 6-month history of poor vision, and referred a great reduction of visual acuity in her right phakic eye. Ophthalmic examination includes best-corrected Snellen visual acuity test and optical coherence tomography (OCT). Visual acuity was 0.05 and OCT scan showed typical features of cystoid macular oedema (CME) (figure 1A). After approval of our Institution Ethical Committee, the patient signed an informed consent form, which included a comprehensive description of dobesilate and the proposed procedure. The patient received an intravitreal solution of dobesilate (150 μl) under sterile conditions, following the International Guidelines for intravitreal injections 1 in her right eye. Dobesilate was administered as a 12.5% solution of diethylammonium 2.5-dihydroxybenzenesulphonate (etamsylate; Dicynone Sanofi-Aventis, Paris, France). After 6 days of treatment vision acuity was improved (0.4) and the structural changes in the fovea resolved with resolution of the intraretinal cystic spaces (figure 1B). Intraocular pressure was 14 mm Hg before treatment, raised to 28 mm Hg after 2 min of injection and returned to baseline 24 h after. No ocular side effects were observed during treatment. The patient was clinically stable on a 10-week follow-up after injection.
DISCUSSION
CME is a common cause of visual loss that is the result of cystic accumulation of extracellular intraretinal fluid predominantly in the outer plexiform and inner nuclear layers of the retina, as a result of the breakdown of the blood retinal barrier. 2 Common causes of CME are postsurgical (cataract, glaucoma and laser surgeries), intraocular inflammatory diseases, medications, diabetic retinopathy, genetic chorioretinal dystrophy (choroideraemia) and retinal vein occlusions. 3 4 Acute CME, defined as oedema of less than 4 months duration, often resolved spontaneously, while CME that persists for 4 months or more is termed as chronic. 5 Different approaches, medical and surgical, are currently used in treating CME. 6 Many studies have shown an association between CME and inflammation. 7 8 For this reason, CME is commonly treated with anti-inflammatory agents. Corticosteroids are, indeed, effective in CME prevention and treatment, 9 but are associated with serious side effects, including elevate ocular pressure, posterior subcapsular cataract and exacerbation of an increased susceptibility to Figure 1 Effect of the intravitreal administration of dobesilate in cystoid macular oedema (CME). Optical coherence tomography (OCT) was used before and after treatment to determine the presence of CME. OCT signs of macular oedema were observed before treatment (A). Resolution of macular oedema was depicted in OCT scan after six days of treatment (B). Horizontal arrows indicate the localisation of the performed OCT scans. concomitant infections. 10 Thus, safer alternative treatments of CME are desirable. The inflammasome, a pathogen and danger-sensing system triggering innate immunity, involves the interaction of immune and tissue cells, as well as the production and release of cytokines and growth factors by the different cell types.
11 Sometimes a feedback mechanism resulting from an over-reaction causes acute inflammation to become chronic, with the subsequent alteration of organs and tissues. In these cases, the suppression of the innate immune response is an inevitable therapeutic objective. The fibroblast growth factor (FGF) is one of the participants of the inflammosome. 11 Gene expression of FGF-stimulated endothelial cells shows, together with a prominent proangiogenic profile, a proinflammatory signature characterised by the upregulation of proinflammatory cytokines/chemokines and their receptors, endothelial cell adhesion molecules and members of the eicosanoid pathway. 12 Furthermore, upregulation of FGF was associated with an increase in the vascular permeability. 13 Thus, inhibition of FGF signals could constitute a therapeutic strategy for attenuating excessive or chronic inflammatory responses.
The rapid resolution of CME after intravitreal administration of dobesilate, a synthetic FGF inhibitor 14 with important antipermeability 15 and anti-inflammatory activities 16 is presented in this case report. Normalising the histological structure of the retina was parallel to a considerable improvement of visual acuity.
The use of dobesilate to treat ocular diseases caused by an excess of angiogenesis has been repeatedly proposed. Nevertheless, a careful clinical study recently published was unable to show that the use of this drug has any significant therapeutic advantage for treating these diseases. 17 In this respect it is necessary to remark that, in that study, dobesilate was orally administered as a calcium salt that is very insoluble at the stomach pH, and that it readily oxidises (and inactivates) once it dissolves when it encounters more alkaline regions of the digestive system. All these limitations in our study are overcome by the direct application to the vitreous of a soluble salt of 2.5-dihydroxybenzenesulfonate.
Learning points
▸ Cystoid macular oedema (CME) is a common cause of visual loss that is the result of cystic accumulation of intraretinal fluid. ▸ Many studies have shown an association between CME and inflammation. ▸ Corticosteroids have been used in the treatment of CME, but are associated with serious ocular side effects. ▸ Fibroblast growth factor (FGF) has been implicated in inflammation. ▸ Dobesilate, a synthetic FGF inhibitor, may offer a therapeutic benefit in macular oedema through its anti-inflammatory and antipermeability activities. Please cite this article as follows (you will need to access the article online to obtain the date of publication). 
